Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New smartphone eye test could bring vision checks to your home

NCT ID NCT06908967

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new smartphone-based device called EyeMirage that uses artificial intelligence to perform eye exams remotely. Researchers compared its results to standard clinic equipment in 160 adults aged 18 to 65. The goal was to see if the device could accurately measure vision, color vision, visual field, and eye movement, potentially allowing people to get eye exams without visiting a clinic.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EyeMirage device (smartphone-based AI eye exam tool)
What this could lead to
If successful, this could enable reliable remote eye exams, making vision testing more accessible for people who cannot easily visit a clinic.
What could go wrong
This is a small, completed study comparing a new device to standard care. The results may not apply to all eye conditions or settings, and the device may not be as accurate as traditional methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

160 people

The number who actually took part.

Started

Jun 2025

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Evidence of a signed and dated informed consent document confirming that the participant has been informed of all aspects of the clinical study. * Male or female participants, 18 to 65 years of age at time of screening. * Visual acuity of 20/200 or better. * Willingness to comply with required screening procedures, eye assessments, and follow-up visits, if needed. Exclusion Criteria: * Visual acuity worse than 20/200 in either eye * Complete blindness or diffuse vision loss in either eye * Clinical diagnosis of cognitive and motor diseases including but not limited to the following: 1. Neurodegenerative diseases such as dementia-like Alzheimer's disease, posterior cortical atrophy 2. Movement disorders such as Parkinson's disease and Parkinsonism tremors 3. Multiple sclerosis, stroke or any other neurological or physical conditions with paresis or plegia (i.e. weakness or paralysis of the limbs) * Eyes with a spherical equivalent of greater than +9 or -9 diopters where the corrective lens is too large to fit in the headset.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Visual function are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Armstrong + Small Eye Care Centre

    Winnipeg, Manitoba, R3G 0S7, Canada

  • Brain, Vision and Concussion Clinic

    Winnipeg, Manitoba, R2M 2X9, Canada

  • Prairie Eye Care (Northgate)

    Winnipeg, Manitoba, R2V 3C4, Canada

  • St. Boniface Eye Care Centre

    Winnipeg, Manitoba, R2H 0S8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.